# Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

> **NCT00523848** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 46 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** bortezomib
- **DRUG:** pegylated liposomal doxorubicin hydrochloride
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00523848
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2011-09
- **Final completion:** 2012-10
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00523848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00523848, "Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00523848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*